|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
TGF-β1-induced phosphorylation of Smad2 and Akt was enhanced in RIG-I-deficient HCC spheres, knockdown of AKT gene expression abolishing the augmentation of TGF-β1-induced Smad2 phosphorylation.
|
31088527 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
And we found that LY2109761 could inhibit cell proliferation by down-regulating the phosphorylation of Smad-2 as well as improved the therapeutic effect of TACE in a VX2 hepatocellular carcinoma model.
|
29416682 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry (IHC), quantitative real-time PCR (qRT-PCR) or Western blot analysis was used to detect TRIM52, p21, matrix metalloproteinase 2 (MMP2), protein phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup> dependent 1A (PPM1A), p-Smad2/3 and Smad2/3 levels in HCC tissues and cell lines.
|
29898761 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In clinical HCC samples, GP73 positively correlated with TGF-β1/Smad2, which was upregulated in HCC.
|
29365054 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Compared with the control, miR-340 was significantly lower in the serum of the HCC patients (p < 0.01). miR-340 was lower in HCC tissues than in adjacent; however, DcR3, TGF-β1 and Smad2 were higher (p < 0.01).
|
29311025 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In analysis of correlation with tumor stage, both protein and mRNA expression of TGFβ1, Smad1, Smad2 and Smad4 in patients with stage III HCC were significantly lower than those with stage IV HCC (P < 0.001), while the protein and mRNA expression of Smad3 in patients with IV stage HCC was significantly higher in comparison to those with stage IV HCC (P < 0.001).
|
29799303 |
2018 |
|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
We predict, based on gene expression data of patient samples, increased amounts of Smad2/3/4 proteins and Smad2 phosphorylation as hallmarks of hepatocellular carcinoma and experimentally verify this prediction.
|
29248373 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, JR inhibits liver cancer cells migration and invasion through epithelial mesenchymal transition (EMT) inhibition via Smad2/3 dependent and independent pathways, suggesting it is an effective therapeutic strategy against HCC metastasis.
|
30174709 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Treatment with the herbal formula Songyou Yin inhibits epithelial-mesenchymal transition in hepatocellular carcinoma through downregulation of TGF-β1 expression and inhibition of the SMAD2/3 signaling pathway.
|
28454396 |
2017 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Curcumin downregulates the expression of Snail via suppressing Smad2 pathway to inhibit TGF-β1-induced epithelial-mesenchymal transitions in hepatoma cells.
|
29312546 |
2017 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The abovementioned phenotypic changes are dependent on increases in epithelial-mesenchymal transition marker gene expression and transforming growth factor-β-Smad2/3 signaling activity in HCC.
|
28945217 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells.
|
28649002 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF-β/Smad2/3 signaling pathway.
|
28903735 |
2017 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigated the functional role of the cyclin D1-dependent activation of Smad2/3 and Smad4 in hepatocellular carcinoma (HCC) CSCs and in HCC primary tumors.
|
28415588 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Consistent with our in vitro data, we demonstrate SCF overexpression and its correlation to SMAD2 and STAT3 activation in human HCC tumors, advanced tumor-node-metastasis stages, and shorter survival.
|
27292026 |
2016 |
|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
Further studies demonstrated that MUC1-mediated JNK activation not only enhances the phosphorylation of Smad2 C-terminal at Ser-465/467 site (Smad2C) through TGF-β/TβRI, but also directly enhances the phosphorylation of Smad2 linker region at Ser-245/250/255 site (Smad2L), and then both of them collaborate to upregulate matrix metalloproteinase (MMP)-9-mediated cell migration and invasion of HCC.
|
26057631 |
2015 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In the presence of LRG, TGFβ1 significantly inhibited the proliferation of LLC cells and human hepatocellular carcinoma Hep3B cells in vitro by inducing apoptosis via the potent activation of smad2 and its downstream signaling pathway.
|
25826092 |
2015 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
A shift in Smad2/3 phosphorylation from the carboxy terminus to linker sites is a key event determining biological function of TGF-β in colorectal and hepatocellular carcinoma.
|
22539990 |
2012 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
RGD |
The expressions of Smad4 and phosphorylated Smad2 in the HCC tissue was significantly lower than those in normal liver tissue.
|
18971187 |
2008 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
The aberrant location of expression and staining intensity of PTEN, PPM1A and P-Smad2 in HCC and their relationship might have an impact on the pathogenesis of HCC.
|
17729405 |
2007 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study identifies activin A as a novel stimulus of vascular endothelial growth factor gene expression in hepatocellular carcinoma and delineates physical and functional cooperation of Sp1 and Smad2 as the underlying mechanism.
|
15188178 |
2004 |
|
Liver carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Using the HepG2 hepatoma cells, we showed here that expression of Smad2.Q407R, a missense mutation found in human hepatocellular carcinoma, was less effective than expression of wild-type Smad2 in enhancing the ability of TGF-beta to induce transcription from the Mix.2 promoter.
|
12700238 |
2003 |
|
Liver carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To investigate the involvement of autocrine TGF-beta signal in cell growth, PAI-1 and VEGF production of HCC, we made stable transfectants of human HCC line (HuH-7 cells) to express a mutant Smad2(3S-A), in which serine residues of SSXS motif were changed to alanine.
|
12700666 |
2003 |
|
Liver carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
However, mechanisms as mutations in TGF-beta receptor II or Smad2 and 4 genes, frequently observed in other human cancers, have only rarely been observed in hepatocellular carcinomas.
|
11170302 |
2001 |
|
Liver carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that mutations of the hsMAD2, hBUB1 and hBUB3 genes are very rare in bladder tumors and that hsMAD2 alterations are also infrequent in soft-tissue sarcomas and hepatocellular carcinomas.
|
11400114 |
2001 |